Aslanipour, BehnazAlan, MuratDemir, Ismail2019-10-272019-10-2720190951-35901473-07660951-35901473-0766https://doi.org/10.1080/09513590.2019.1665646https://hdl.handle.net/11454/28594Liver-expressed antimicrobial peptide 2 (LEAP-2) is a newly identified peptide hormone involved in glucose metabolism. It acts as a noncompetitive antagonist of ghrelin hormone's receptor. Polycystic ovary syndrome (PCOS) is a common metabolic and reproductive disease associated with insulin resistance. We aimed to compare circulating LEAP-2 levels in subjects with PCOS and controls. We also focused to determine whether there was a relationship between LEAP-2 and metabolic parameters in women with PCOS. We enrolled 64 subjects with PCOS and 64 age and body mass index (BMI)-matched controls into the current cross-sectional study. Circulating LEAP-2 and ghrelin levels were measured via ELISA method. Metabolic and hormonal parameters of the involved subjects were analyzed. We found that circulating LEAP-2 and ghrelin levels were decreased in women with PCOS as compared with controls. LEAP-2 showed a positively independent association with ghrelin while LEAP-2 exhibited an inverse association with insulin resistance, BMI, and free-androgen index (FAI). Additionally, subjects having the lowest tertile of LEAP-2 were in positive link of developing PCOS risk with respect to those subjects having the highest tertile of LEAP-2 levels. Decreased LEAP-2 levels were associated with a high possibility of having PCOS risk associated with insulin resistance.en10.1080/09513590.2019.1665646info:eu-repo/semantics/openAccessPolycystic ovary syndromeLEAP-2ghrelininsulin resistancebody mass indexArticleWOS:000486836800001Q3